邓燕莉,王婕,魏上斐,翟鑫
DENG Yanli,WANG Jie,WEI Shangfei,ZHAI Xin

• 1:辽宁中医药大学附属第三医院制剂中心
• 2:沈阳药科大学基于靶点的药物设计与研究教育部重点实验室

摘要(Abstract)：

目的 对变构激酶抑制剂的特点及研究现状进行综述，期望能为高效的变构激酶抑制剂的研发提供参考。方法 查阅国内外相关文献，对蛋白激酶抑制剂的结合方式、结构特点、研究进展等方面进行总结和分析。结果 变构调节作为一种高效调节机制，可通过结合于不同催化位点的变构位点使蛋白质的构象发生变化而发挥调节活性，从而保证细胞正常功能运行。由于不与激酶催化位点重合，靶向蛋白激酶结构中的变构位点能够获得较传统ATP竞争性抑制剂具有更高选择性和活性的变构激酶抑制剂。结论 基于变构调节机制，靶向变构位点的变构激酶抑制剂可作为新药开发的重要策略。
Objective To review the development of allosteric inhibitors based on chemical structures in aim of provide reference for developing allosteric inhibitors with better properties.Methods Referring to relevant literatures, the classification of kinases inhibitors is covered.Chemical structures, binding modes and interactions of allosteric inhibitors of kinases are described briefly.Results Allostery is the inherent property and effective regulatory mechanisms in cells.Binding to an allosteric site which is pographically distinct from orthoseric site, the allosteric ligand change the conformation of receptor/protein in controlling of several biomolecule functions.Targeting the allosteric sites in kinases give way to develop allosteric inhibitors with higher selectivity and more potent activity compared to traditional ATP competitive inhibitors.Conclusion Based on allostery, the allosteric kinase inhibitors become an important and effective strategy for drug development.

关键词(KeyWords)： 变构激酶抑制剂;设计优化;结合模式;相互作用
allosteric kinases inhibitors;design and optimization;binding mode;interactions

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 邓燕莉,王婕,魏上斐,翟鑫
DENG Yanli,WANG Jie,WEI Shangfei,ZHAI Xin

DOI: 10.14066/j.cnki.cn21-1349/r.2021.0748

参考文献(References)：

• [1] LI X,CHEN Y,LU S,et al.Toward an understanding of the sequence and structural basis of allosteric proteins[J].J Mol Graph Model,2013,40(1):30-39.
• [2] YUEH C,RETTENMAIER T J,XIA B,et al.Kinase atlas:druggability analysis of potential allosteric sites in kinases[J].J Med Chem,2019,62(14):6512-6524.
• [3] NUSSINOV R,TSAI C J.Allostery in disease and in drug discovery.[J].Cell,2013,153(2):293-305.
• [4] NUSSINOV R,TSAI C J,XIN F,et al.Allosteric post-translational modification codes[J].Trends Bio Chem Sci,2012,37(10):447-455.
• [5] GUARNERA E,BEREZOVSKY I N.Toward comprehensive allosteric control over protein activity[J].Structure,2019.27(5):866-878.
• [6] VANDANA L,INDRANEEL G.New directions in targeting protein kinases:focusing upon true allosteric and bivalent inhibitors.[J].Curr Pharm Design,2012,18(20):2936-2945.
• [7] FANG Z,TTER C,RAUH D.Strategies for the selective regulation of kinases with allosteric modulators:exploiting exclusive structural features[J].ACS Chem Bio,2013,8(1):58-70.
• [8] GUARNERA E,BEREZOVSKY I N .Allosteric sites:remote control in regulation of protein activity[J].Curr Opin Struc Bio,2016,37:1-8.
• [9] WEI Y,RAJIV L N,FRANCESCA C,et al.Insights into current tropomyosin receptor kinase(TRK)inhibitors:development and clinical application[J].J Med Chem,2019,62:1731-1760.
• [10] SU H P,RICKERT K,BURLEIN C,et al.Structural characterization of nonactive site,TrkA-selective kinase inhibitors[J].Proc Natl Acad Sci USA,2017,114(3):E297-306.
• [11] FURUYA N,MOMOSE T,KATSUNO K,et al.The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity[J].Bioorg Med Chem Lett,2017,27(5):1233-1236.
• [12] BAGAL S K,OMOTO K,BLAKEMORE D C,et al.Discovery of allosteric,potent,subtype selective and peripherally restricted trka kinase inhibitors[J].J Med Chem,2018,62(1):247-265.
• [13] X CHEN,LI C,WANG D,et al.Recent advances in the discovery of CK2 allosteric inhibitors:from traditional screening to structure-based design[J].Molecules,2020,25(4):870.
• [14] FUSCO C D,BREAR P,IEGRE J,et al.A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066[J].Bioorg Med Chem,2017,25(13):3471-3482.
• [15] IEGRE J,BREAR P,FUSCO C D,et al.Second-generation CK2α inhibitors targeting the αD pocket[J].Chem Sci,2018,9:3041-3049.
• [16] BESTGEN B,KUFAREVA I,SEETOH W G,et al.2-Aminothiazole derivatives as selective allosteric modulators of the protein kinase CK2.2.structure-based optimization and investigation of effects specific to the allosteric mode of action[J].J Med Chem,2019,62(4):1817-1836.
• [17] BESTGEN B,KRIMM I,KUFAREVA I,et al.2-Aminothiazole derivatives as selective allosteric modulators of the protein kinase CK2.Part 1:identification of an allosteric binding site[J].J Med Chem,2019,62(4):1803-1816.
• [18] SEBOLT-LEOPOLD J S,HERRERA R.Targeting the mitogen-activated protein kinase cascade to treat cancer.[J].Nat Rev Cancer,2004,4(12):937-947.
• [19] OHREN J F,CHEN H,PAVLOVSKY A,et al.Structures of human MAP kinase kinase 1(MEK1)and MEK2 describe novel noncompetitive kinase inhibition.[J].Nat Struct Mol Bio,2004,11(12):1192-1197.
• [20] THOTA R,JOHNSON D B,SOSMAN J A .Trametinib in the treatment of melanoma[J].Expert Opinion on Biological Therapy,2016,15(5):735-747.
• [21] SIGNORELLI J,GANDHI A S.Cobimetinib:a novel MEK inhibitor for metastatic melanoma[J].Ann Pharmacother,2016,51,(2):146-153.
• [22] RICE K D,AA Y,ANAND N K,et al.Novel carboxamide-based allosteric mek inhibitors:discovery and optimization efforts toward XL518(GDC-0973)[J].ACS Med Chem Lett,2012,3(5):416-421.
• [23] MARKHAM A,KEAM S J.Selumetinib:first approval[J].Drugs,2020,80(8):931-937.
• [24] HERPEN C,AGARWALA S S,HAUSCHILD A,et al.Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib(MEK162)in patients with advanced NRAS- or BRAF-mutated melanoma[J].Oncotarget,2019,10(19):1850-1859.
• [25] IVERSON C,LARSON G,LAI C,et al.RDEA119/BAY 869766:a potent,selective,allosteric inhibitor of MEK1/2 for the treatment of cancer[J].Cancer Res,2009,69(17):6839-6847.
• [26] FRUSCIA P D,EDFELDT F,SHAMOVSKY I,et al.Fragment-based discovery of novel allosteric mek1 binders[J].ACS Med Chem Lett,2021,12:302-308.
• [27] HANTSCHEL O,SUPERTI-Furga G.Regulation of the c-Abl and Bcr-abl tyrosine kinases[J].Nat Rev Mol Cell Biol,2004,5(1):33-44.
• [28] ADRIN F J,DING Q,SIM T,et al.Allosteric inhibitors of Bcr-abl-dependent cell proliferation[J].Nat Chem Bio,2006,2(2),95-102.
• [29] KANTARJIAN H M,BACCARANI M,JABBOUR E,et al.Second-generation tyrosine kinase inhibitors:The future of frontline CML therapy[J].ASCO,2011,17(7):1674-83.
• [30] SCHOEPFER J,JAHNKE W,BERELLINI G,et al.Discovery of asciminib(ABL001),an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1[J].J Med Chem,2018,61:8120-8135.
• [31] FALLACARA A L,TINTORI C,RADI M,et al.Insight into the allosteric inhibition of Abl kinase[J].J Chem Inf Model,2014,54(5):1325-1338.
• [32] ZHOU J,YI Q,TANG L.The roles of nuclear focal adhesion kinase(FAK)on cancer:a focused review[J].J Exp Clin Canc Res,2019,38(1):250-251.
• [33] TOMITA N,HAYASHI Y,SUZUKI S,et al.Structure-based discovery of cellular-active allosteric inhibitors of FAK[J].Bioorg Med Chem Lett,2013,23(6):1779-1785.
• [34] RADU M,SEMENOVA G,KOSOFF R,et al.PAK signalling during the development and progression of cancer[J].Nat Rev Cancer,2014,14(1):13-25.
• [35] KARPOV A S,AMIRI P,BELLAMACINA C,et al.Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor[J].ACS Med Chem Lett,2015,6(7):776-781.
• [36] YAMADA K,PARK H,RIGEL D F,et al.Small-molecule WNK inhibition regulates cardiovascular and renal function[J].Nat Chem Biol,2016,12(11):896-898.
• [37] YAMADA K,ZHANG J H,XIE X,et al.Discovery and characterization of allosteric WNK kinase inhibitors[J].Acs Chem Bio,2016,11:3338-3346.
• [38] YAMADA K,LEVELL J,YOON T,et al.Optimization of allosteric with-no-lysine(WNK)kinase inhibitors and efficacy in rodent hypertension models[J].J Med Chem,2017,60:7099-7107.
• [39] JUILLET C,ERMOLENKO L,BOYARSKAYA D,et al.From synthetic simplified marine metabolite analogues to new selective allosteric inhibitor of aurora B kinase[J].J Med Chem,2021,64:1197-1219.